Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5168
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies.

    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
A&G Pharmaceutical
AB Science
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardea Biosciences
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bayer
Berkeley Lab
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Bionovo
BioNumerik
BioSante
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CompleGen
Cornerstone Pharmaceuticals
CritiTech
CSL
Cue Biotech
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dompe
Dr Reddy’s
Dyax
EGEN Inc
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
Galectin Therapeutics
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Green Cross
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Innate Pharma
InNexus Biotechnology
Innovive
Insmed
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
Kaketsuken
KaloBios
Karus Therapeutics
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Lorus Therapeutics
MacroGenics
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Morvus Technology
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Neuren
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
Pharmacyclics
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
Ramot
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VaxOnco
VBL Therapeutics
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
ViroMed
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zeria
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
adecatumumab
AEG-35156
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
Angiozyme
apatinib
apricoxib
ARC-100
ARQ-197
atrasentan
AV-299
axitinib
bardoxolone methyl
belimumab
bevacizumab
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
BT-062
Cabozantinib
capecitabine
carlumab
catumaxomab
CDX-1307
CDX-1401
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
CPI-613
CRLX-101
CT-011
dalotuzumab
daratumumab
dasatinib
denosumab
DI-17E6
docetaxel
dovitinib lactate
doxorubicin
E-7820
elotuzumab
EMD-273063
EMD525797
endostatin
eniluracil
ENMD-2076
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
erlotinib
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganitumab
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
GS-6634
GSK-1120212
GT-111
GV-1001
GVAX
HBP-347
I-131-labetuzumab
ibritumomab tiuxetan
icotinib hydrochloride
icrucumab
imatinib mesilate
IMP-321
inotuzumab ozogamicin
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
irinotecan
irinotecan hydrochloride
JI-101
KD032
L19-IL2
L19-TNFalpha
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
masitinib
MCS-110
MEDI-551
MEDI-573
MetXia
MGCD-265
midostaurin
milatuzumab
milatuzumab-doxorubicin
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
motexafin gadolinium
moxetumomab pasudotox
muparfostat (IV)
nadroparin
naptumomab estafenatox
natalizumab
necitumumab
NGR-TNF
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
olaratumab
ON-01910
onartuzumab
Onyvax-105
oregovomab
OTS-102
P-276-00
paclitaxel
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
PF-4856884
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-12
RAF-265
ramucirumab
Reditux
regorafenib
Rexin-G
RG-7160
ridaforolimus
rilotumumab
rituximab
robatumumab
romidepsin
romiplostim
RX-0201
samalizumab
SAR-3419
selumetinib
siltuximab
sirolimus
sorafenib tosylate
sotatercept
ß-lapachone
SU-6668
sunitinib malate
Sym-004
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
varlitinib
veltuzumab
vismodegib
volociximab
WX-671
XL-184
XL-647
yttrium Y 90 clivatuzumab tetraxetan
Z-360
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies.
    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Prostate Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More


Triple Analysis: Breast Cancer, Leukemia and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Pancreatic Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More


The Complete Guide to Targeted Therapies in Oncology: A World Review
In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology. Learn More